Telbivudine

Antiviral, Systemic · Nucleoside reverse transcriptase inhibitor

Indications

Treatment of chronic hepatitis B in patients with evidence of viral replication & active liver inflammation.

Dosage

Adults: 600 mg once daily. Renal impairment: CrCl 30-49: 600 mg once every 48 hr; CrCl <30 (not requiring dialysis): 600 mg once every 72 hr. End stage renal disease: 600 mg once every 96 hr, administered after haemodialysis. Children: Not recommended.

Adverse Effects

Dizziness, headache, increased blood amylase & lipase, diarrhoea, nausea; increased liver enzymes; increased blood creatine phosphokinase; rash, fatigue, cough, GI upset.

Risk Factor (Pregnancy/Lactation)

Pregnancy: Risk cannot be ruled out. Lactation: Caution advised or effect undetermined. Contraindications: Lamivudine-resistant hepatitis B. Precautions: Monitor hepatic function in patients who have discontinued anti-hepatitis B therapy. Lactic acidosis, severe hepatomegaly with steatosis, myopathy, uncomplicated myalgia. Renal impairment. Patients with antiviral-resistant. HBV infection. Liver transplant recipient. Elderly.

Interactions

Interferon alfa, aminoglycosides, loop diuretics, platinum compounds, vancomycin, amphotericin B, other drugs that effect renal function, lamivudine.

Advice to Patient

Take with or without meals. Avoid alcohol. If a dose is missed, take it as soon as you remember unless it is almost time for the next dose. Do not take double dose. Contact prescriber if there is hives, difficulty in breathing, swelling on face/lips/tongue/throat, muscle pain or weakness, numb or cold feeling in arms and legs, dizziness, light-headed, and tiredness.

Pharmacokinetics

Absorption: Rapidly absorbed from the GI tract. Half-life elimination: Terminal: 30-53.6 hrs. Time to peak, plasma: 3 hrs. Excretion: Urine (mainly).

Brands with this active ingredient

• Sebivo
• Taboval

Compiled by Healify Pharmacy from published drug references. How we compile it →

Always consult a pharmacist or doctor.